|Bid||0.0130 x 125665700|
|Ask||0.0140 x 8008500|
|Day's range||0.0090 - 0.0130|
|52-week range||0.0070 - 0.0280|
|Beta (5Y monthly)||1.22|
|PE ratio (TTM)||N/A|
|Earnings date||28 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.04|
MGC Pharmaceuticals ( ASX:MXC ) First Half 2023 Results Key Financial Results Revenue: AU$2.66m (up 3.8% from 1H 2022...
MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), is a European based bio-pharma company, focused on developing and supplying affordable (Accessible) and Ethically Produced Plant Inspired Medicines, is helping to solve the mystery of treating Long COVID patients with a new herbal inspired medicine.
MGC Pharmaceuticals Ltd. (LSE: MXC, ASX: MXC, OTC:MGCLF), a European based bio-pharma company specializing in the production and development of phytomedicines, has signed an exclusive distribution agreement with Sciensus Rare, a part of UK health care group, Sciensus, for the distribution of CannEpil® and CogniCann® in key European territories and the UK.